[The transparency committee of the French National Authority for Health]. / La Commission de la transparence de la Haute Autorité de santé.

ABSTRACT

The Transparency Committee (TC) in France plays a crucial role in the evaluation of post-market authorization (MA) drugs for reimbursement by the social security system. Although its organization has evolved since its creation, the principle of its existence has persisted since the establishment of the social security system. The TC, transitioning from the Medicines Agency to the Haute Autorité de santé in 2005, focuses on the medico-scientific evaluation of drugs, influencing decisions on reimbursement eligibility and price negotiations. It assesses the benefit and added medical value of drugs. Comprising experts with no conflicts of interest with pharmaceutical companies, the TC conducts a scientific evaluation of submissions by pharmaceutical laboratories. Recently, it has also been involved in evaluating requests for early access authorization prior to MA.